


**Fig. 1**


**DMPC+ G17-DT (LIPID/PROTEIN RATIO 500:1)**



**BEST AVAILABLE COPY**


**Fig. 2**

**DMPC +G17-DT + nor -MDP (LIPID/PROTEIN RATIO 500:1)**




**Fig. 3**

**DMPC/DMPG + G17-DT (LIPID/PROTEIN RATIO 500:1)**



**Fig. 4**

**DMPC / DMPG +G17-DT+ nor-MDP (LIPID/PROTEIN RATIO 500:1)**



**Fig. 5**

**GROUP MEAN ANTI-GASTRIN ANTIBODY TITERS (Example 3)**






Fig. 6

GROUP MEDIAN ANTI-GASTRIN ANTIBODY TITERS (Example 3)



**Fig. 7**

**GROUP MEAN ANTI-GnRH ANTIBODY TITERS (Example 5)**



**Fig. 8**

**GROUP MEDIAN ANTI-GnRH ANTIBODY TITERS (Example 5)**






Fig. 9: HIGH DOSE G17DT LIPOSOMES & RECONSTITUTION




Fig. 9: HIGH DOSE G17DT LIPOSOMES RECONSTITUTED WITH H<sub>2</sub>O or 5% EtOH  
(EXAMPLE 6)




Fig. 10: HIGH DOSE G17DT LIPOSOMES PECONSTITUTION WITH H<sub>2</sub>O OR 5% EtOH




Fig. 10: HIGH DOSE LIPOSOMES RECONSTITUTED WITH H<sub>2</sub>O or EtOH

(EXAMPLE 6)

